Personal information

No personal information available

Activities

Collapse all

Employment (1)

Cleveland Clinic: Cleveland, OH, US

Director, Mellen Center for Multiple Sclerosis (Neurology)
Employment
Source: Self-asserted source
Robert Bermel

Works (50 of 261)

Items per page:
Page 1 of 6

A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis

Multiple Sclerosis Journal
2025-01 | Journal article
DOI: 10.1177/13524585241301854
Contributors: Xiaotong Jiang; Marisa McGinley; Joshua Johnston; Jay Alberts; Robert Bermel; Daniel Ontaneda; Robert T Naismith; Robert Hyde; Nick Levitt; Johan van Beek et al.
Source: check_circle
Crossref

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

Neurology
2024-12-24 | Journal article
DOI: 10.1212/WNL.0000000000210049
Contributors: Hans-Peter Hartung; Ralph H.B. Benedict; Thomas Berger; Robert A. Bermel; Bruno Brochet; William M. Carroll; Mark S. Freedman; Trygve Holmøy; Rana Karabudak; Carlos Nos et al.
Source: check_circle
Crossref

A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis

Multiple Sclerosis Journal
2024-03 | Journal article
DOI: 10.1177/13524585241227372
Contributors: Kian Jalaleddini; Robert A Bermel; Bari Talente; David Weinstein; Ferhan Qureshi; Maital Rasmussen; Sreeranjani Menon; Miyuru Amarapala; Kesshi Jordan; Ati Ghoreyshi et al.
Source: check_circle
Crossref

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials

Therapeutic Advances in Neurological Disorders
2024-01 | Journal article
DOI: 10.1177/17562864241277736
Contributors: Tobias Derfuss; Robert Bermel; Chien-Ju Lin; Stephen L. Hauser; Ludwig Kappos; Timothy Vollmer; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Martin S. Weber et al.
Source: check_circle
Crossref

The relationship between cognition, education, and employment in multiple sclerosis patients

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2022-07 | Journal article
DOI: 10.1177/20552173221118309
Contributors: Devon S Conway; Robert A Bermel; Sarah M Planchon
Source: check_circle
Crossref

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Multiple Sclerosis Journal
2022-06 | Journal article
DOI: 10.1177/13524585211061343
Contributors: Jeffrey A Cohen; Robert A Bermel; Cynthia I Grossman; Carrie M Hersh; Megan Hyland; Ellen M Mowry; Robert Naismith; Maria L Naylor; Jacqueline Nicholas; Rajani Rajbhandar et al.
Source: check_circle
Crossref

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Multiple Sclerosis Journal
2022-04 | Journal article
DOI: 10.1177/13524585211035740
Contributors: Bianca Weinstock-Guttman; Robert Bermel; Gary Cutter; Mark S Freedman; Thomas P Leist; Xiaoye Ma; Deidre Kile; Bruno Musch; Anthony T Reder; Jerry S Wolinsky
Source: check_circle
Crossref

DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – No

Multiple Sclerosis Journal
2022-02 | Journal article
DOI: 10.1177/13524585211062169
Contributors: Robert A Bermel
Source: check_circle
Crossref

How patients with multiple sclerosis acquire disability

Brain
2022-02-01 | Journal article
DOI: 10.1093/brain/awac016
Contributors: Fred D. Lublin; Dieter A. Häring; Habib Ganjgahi; Alex Ocampo; Farhad Hatami; Jelena Čuklina; Piet Aarden; Frank Dahlke; Douglas L. Arnold; Heinz Wiendl et al.
Source: check_circle
Crossref

Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2021-10 | Journal article
DOI: 10.1177/20552173211057110
Contributors: Deja R Rose; Ahmad Z Mahadeen; Alise K Carlson; Sarah M Planchon; Jennifer Sedlak; Scott Husak; Robert A Bermel; Jeffrey A Cohen; Brandon P Moss
Source: check_circle
Crossref

Use of a Smartphone to Gather Parkinson’s Disease Neurological Vital Signs during the COVID-19 Pandemic

Parkinson's Disease
2021-04-10 | Journal article
DOI: 10.1155/2021/5534282
Contributors: Jay L. Alberts; Mandy Miller Koop; Marisa P. McGinley; Amanda L. Penko; Hubert H. Fernandez; Steven Shook; Robert A. Bermel; André Machado; Anson B. Rosenfeldt; Pablo Mir
Source: check_circle
Crossref

<? covid19?> Multiple sclerosis management during the COVID-19 pandemic

Multiple Sclerosis Journal
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Ageing and multiple sclerosis

Multiple sclerosis and related disorders
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Cognitive processing speed in multiple sclerosis clinical practice: association with patient-reported outcomes, employment and magnetic resonance imaging metrics

European Journal of Neurology
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases

PloS one
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS

EUROPEAN JOURNAL OF NEUROLOGY
2020 | Conference paper
Source: Self-asserted source
Robert Bermel

Harnessing real-world data to inform decision-making: Multiple sclerosis partners advancing technology and health solutions (MS PATHS)

Frontiers in neurology
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Implementation and patient experience of outpatient teleneurology

Telemedicine and e-Health
2020 | Journal article
Source: Self-asserted source
Robert Bermel

MRI Changes Over the Disease Course in a Large Multiple Sclerosis Clinical Cohort (2221)

2020 | Other
Source: Self-asserted source
Robert Bermel

Multiple sclerosis management during the COVID-19 pandemic

Multiple Sclerosis (Houndmills, Basingstoke, England)
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules

European Journal of Neurology
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Novel Biomechanical Outcomes for Upper Extremity Function (4762)

2020 | Other
Source: Self-asserted source
Robert Bermel

Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry (1300)

2020 | Other
Source: Self-asserted source
Robert Bermel

Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials

Multiple Sclerosis Journal
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Quantitative MRI in Multiple Sclerosis Patients with Hypertension (4139)

2020 | Other
Source: Self-asserted source
Robert Bermel

Routine Cognitive Processing Speed Assessment in Clinical Practice is Associated with Patient Reported Outcome, Employment, and Quantitative MRI

Multiple Sclerosis and Related Disorders
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Serum Ig Levels and Risk of Serious Infections by Baseline Ig Quartile in the Pivotal Phase III Trials and Open-Label Extensions of Ocrelizumab in Multiple Sclerosis (1173)

2020 | Other
Source: Self-asserted source
Robert Bermel

Shorter Infusion Time of Ocrelizumab: Primary Results from the ENSEMBLE PLUS Study in Patients with Relapsing-Remitting Multiple Sclerosis.

International Journal of MS Care
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Structured Reporting in Multiple Sclerosis Reduces Interpretation Time

Academic Radiology
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Technology-enabled assessments to enhance multiple sclerosis clinical care and research

Neurology: Clinical Practice
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice

Multiple sclerosis and related disorders
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Teleneurology as a solution for outpatient care during the COVID-19 pandemic

Telemedicine and e-Health
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Two-year results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy (2906)

2020 | Other
Source: Self-asserted source
Robert Bermel

Vitamin D and Visual System Measures in Progressive Multiple Sclerosis: A Cross-Sectional Study

International Journal of MS Care
2020 | Journal article
Source: Self-asserted source
Robert Bermel

Assessment of low contrast visual sensitivity

2020-06 | Other
Source: Self-asserted source
Robert Bermel

A Quantitative View of MS Disease Course

MULTIPLE SCLEROSIS JOURNAL
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up

Journal of the neurological sciences
2019 | Journal article
Source: Self-asserted source
Robert Bermel

Comprehensive Assessments in Clinic Using Technology-Enabled Neuroperformance Testing, Patient Reported Outcomes, and Advanced MRI

MULTIPLE SCLEROSIS JOURNAL
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Comprehensive Assessments in Clinic Using Technology-Enabled Neuroperformance Testing, Patient Reported Outcomes, and Quantitative MRI

ACTRIMS Forum 2019
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Correlation of Physical Disability Measures with Processing Speed Test Performance in a Large MS Polulation

ACTRIMS Forum 2019
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Cross-sectional predictive value of clinically meaningful change in processing speed on self-reported cognition and MRI metrics

MULTIPLE SCLEROSIS JOURNAL
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Discontinuation and Comparative Effectiveness of Dimethyl Fumarate and Fingolimod in Two Large Academic Medical Centers at 36-month Follow-Up (P3. 2-065)

2019 | Other
Source: Self-asserted source
Robert Bermel

Effect of ibudilast on macular measures in progressive MS: OCT analysis from a phase II trial (P3. 2-049)

2019 | Other
Source: Self-asserted source
Robert Bermel

Effect of Ibudilast on neurofilament-light chain in progressive MS: analysis from a phase II trial (P3. 2-033)

2019 | Other
Source: Self-asserted source
Robert Bermel

ENSEMBLE baseline results and ENSEMBLE PLUS study design: an investigation of shorter ocrelizumab infusion time in patients with relapsing-remitting multiple sclerosis

EUROPEAN JOURNAL OF NEUROLOGY
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

ENSEMBLE Baseline Results and ENSEMBLE PLUS Study Design: An Investigation of Shorter Ocrelizumab Infusion Time in Patients With Relapsing-Remitting Multiple Sclerosis

2019 Annual Meeting of the Consortium of Multiple Sclerosis Centers
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Evaluating meaningful change in Neuro-QoL CAT-administered item banks among individuals with Multiple Sclerosis at the group level

QUALITY OF LIFE RESEARCH
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Evaluation of shorter infusion times for Ocrelizumab treatment in an extension substudy of the phase IIIb CHORDS trial

MULTIPLE SCLEROSIS JOURNAL
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Evaluation of shorter infusion times with ocrelizumab in patients with multiple sclerosis

Poster presented at: AAN Annual Meeting
2019 | Conference paper
Source: Self-asserted source
Robert Bermel

Evaluation of shorter infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis (P3. 2-034)

2019 | Other
Source: Self-asserted source
Robert Bermel
Items per page:
Page 1 of 6
How many people are using ORCID?